Highlights Field Trip Health Ltd. Canadian Securities Exchange

Equities

FTRP

CA31656R1029

End-of-day quote Canadian Securities Exchange Other stock markets 23:00:00 07/07/2021 BST			5-day change	1st Jan Change
6.65 ^CAD	+6.40%		+0.36%	+32.78%

05-20	Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders	CI
05-02	Reunion Neuroscience Inc. Announces Advancing RE104, Its Proprietary, Clinical-Stage Serotonergic Psychedelic Drug Candidate to Provide Benefits to Patients with Underserved Mental Health Disorders	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders	05-20	CI
Reunion Neuroscience Inc. Announces Advancing RE104, Its Proprietary, Clinical-Stage Serotonergic Psychedelic Drug Candidate to Provide Benefits to Patients with Underserved Mental Health Disorders	05-02	CI
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression	18/09/23	CI
Reunion Neuroscience Brief: Reunion and MPM BioImpact Complete Plan of Arrangement Effective Today, whereby MPM Acquired Reunion in an all-cash transaction valued at Near US$13.1 million	01/08/23	MT
MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. in a going private transaction.	31/07/23	CI
Reunion Neuroscience Gets Ontario Court's Final Approval for Acquisition by MPM BioImpact	14/07/23	MT
Reunion Neuroscience Brief: Adds In "Assuming Remaining Conditions Precedent Are Satisfied Or Waived", Anticipates Closing of Arrangement Will Occur On Or About July 21, 2023	14/07/23	MT
Reunion Neuroscience Brief: Says Obtained Final Court Order for Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Deal Valued at Near US$13.1 Million	14/07/23	MT
Reunion Neuroscience Brief: Arrangement remains subject to receipt of a final order of the Ontario Superior Court of Justice (Commercial List); Expected to be completed on or around July 21, 2023	13/07/23	MT
Reunion Neuroscience Brief: Shareholders Approve Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Tansaction Valued at Near US$13.1 Million	13/07/23	MT
Reunion Reports Q4 Results; Shareholders to Get US$1.12 Cash Per Share From Arrangement Agreement with MPM BioImpact	29/06/23	MT
Reunion Neuroscience Brief: Adds It Presented "Encouraging" Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting	29/06/23	MT
Reunion Neuroscience Brief: Common Holders to Receive Consideration of US$1.12 Per Share in Cash from Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12	29/06/23	MT
Reunion Neuroscience Brief: Says incurred a net loss from continuing operations of $6.5 million or $0.56 per share and $38.1 million or $3.28 per share for the three and 12 month periods ended March 31, 2023	29/06/23	MT
Reunion Neuroscience Brief: Says Rcognized a net loss from discontinued operations of $10.4 million for the 12 month period ended March 31, 2023; Adds No such loss was incurred during the three month period ended March	29/06/23	MT
Reunion Neuroscience Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	27/06/23	CI
Reunion Neuroscience Up More Than 50% In US Pre-Market After Announcing US$13.1 Million Take-Private Transaction with MPM BioImpact	01/06/23	MT
Reunion Neuroscience Brief: Up 60% In US Pre-Market After Announcing US$13.1 Million Take-Private Transaction with MPM BioImpact; Reunion Common Holders to Get Consideration of US$1.12 Per Share in Cash	01/06/23	MT
Reunion Neuroscience Brief: Says Presented 'Encouraging" Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into Phase 2 in 2H 2023	01/06/23	MT
Reunion Neuroscience Brief: Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price	01/06/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Field Trip Health Ltd. Canadian Securities Exchange

Equities

FTRP

CA31656R1029

Highlights

Filters